Korro Bio KRRO 深 沪
交易中 10-14 10:12:28 美东时间
8.70
-0.110
-1.25%
华盛通- 最 高9.03
- 今 开8.62
- 成交量 1.02万股
- 最 低 8.62
- 昨 收 8.81
- 总市值 1.28亿
- 52周最高 42.70
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 5.2044
- 委 比 -35.28%
- 总股本 1472.56万
- 历史最高 2918.50
- 量 比 0.92
- 振 幅 4.65%
- 历史最低 5.2044
- 每 手 1
- 风险率 8.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗看高AMD至800美元！富国上调Meta目标价至1000美元
今日重点评级关注：Jones Trading：维持Opus Genetics"买入"评级，目标价从10美元升至17美元；Citizens：维持Rezolute"跑赢大市"评级，目标价从11美元升至15美元
10-07 17:30
Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, announced today that the first cohort of participants has be...
10-06 04:10
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Korro Bio has initiated a Phase 1/2 clinical trial for KRRO-121, an RNA-editing oligonucleotide targeting hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE). The trial, named ANCHOR, includes two parts: Part 1 evaluates safety and pharmacokinetics in healthy volunteers, with the first cohort dosed at 2mg/kg. Part 2 will assess safety, tolerability, and clinical activity in UCD patients, expected to begin d...
10-05 20:05
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio granted nonstatutory stock options to three new employees, allowing them to purchase 5,000 shares at $12.93 per share. The options vest over four years and were approved under the 2026 Inducement Plan. Korro, a biopharmaceutical company, uses its OPERA platform to develop genetic medicines targeting rare and prevalent diseases by editing RNA for precise and transient single base edits.
09-11 20:05
Korro to Participate in Upcoming Investor Conferences
Korro Bio, Inc. (KRRO) announced that its CEO, Ram Aiyar, will participate in two investor conferences: the Citi 2026 Biopharma Back to School Summit on September 9th and the 2026 Cantor Global Healthcare Conference on September 10th. Korro, a biopharmaceutical company, utilizes its OPERA® platform to develop RNA-editing therapies for rare and prevalent diseases. The platform enables precise, transient mRNA modifications to enhance protein functi...
08-27 11:00
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $15 price target.
08-20 19:39
Korro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.31) by 18.32 percent. This is a 60.95 percent increase over losses of $(2.74) per share from the same period last year.
08-06 19:28
Korro Bio shares are trading lower after a Form 4 filing showed its President and CEO sold 15,152 shares at an average price of $12.98 each.
Korro Bio shares are trading lower after a Form 4 filing showed its President a...
06-03 02:50
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
